MOUNTAIN VIEW, Calif. -- NeuroPace, Inc., (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17.00 per share. All shares of common stock are being offered by NeuroPace for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and offering expenses. In addition, NeuroPace has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. NeuroPace’s common stock is expected to begin trading on the Nasdaq Global Select Market on April 22, 2021, under the ticker symbol “NPCE”. The offering is expected to close on April 26, 2021, subject to the satisfaction of customary closing conditions.
J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the offering. Wells Fargo Securities and SVB Leerink are also acting as book-running managers for the offering.
Registration statements relating to the shares being sold in this offering have been filed with the Securities and Exchange Commission and declared effective. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, via telephone at +1 (866) 718-1649 or by email at prospectus@morganstanley.com.